Navigation Links
DURECT Corporation to Participate in Upcoming Healthcare Conferences
Date:9/17/2009

CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

  • Matt Hogan, Chief Financial Officer, will present at the UBS Global Life Sciences Conference in New York on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

  • Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled "Issues and Challenges with Clinical Drug Development of Pain Compounds: Failure in Phase III and the Cart before the Horse" at Arrowhead's 3rd Annual Pain Therapeutics Summit in Summit, New Jersey on Friday, September 25th at 8:40 am Eastern Time.

About DURECT

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 Million
2. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
3. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
4. DURECT Corporation Announces Second Quarter 2009 Financial
5. DURECT to Present at the BMO Capital Markets Healthcare Conference
6. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
7. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
8. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
9. DURECT to Participate in Cowen and Company Healthcare Conference
10. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
11. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , ... August 23, 2017 , ... Drs. Steven White ... in Cornelius, NC. By taking advantage of this offer, valued at more than ... regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening procedure. ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... to prove the safety and efficacy of HBOT in treating and helping to ... US, points to research showing the similarities of the wounds to the brain ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the winners ... Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs were ... by a points system based on the total number of awards won in the IBAs ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., a ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . The ... comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s fifth ...
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine ... nationally that earned the designation of High Performing Hospitals by U.S. News & World ... indicates a hospital was significantly better than the national average in a given ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology: